anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Kidney stones and infections significantly affect patients' health-related quality of life (HRQOL); however, the relationship between urinary tract infections (UTIs) and HRQOL in patients with kidney stones remains unclear. This study aimed to investigate the relationship using the validated Chinese version of the Wisconsin Stone Quality of Life questionnaire (C-WISQOL). We prospectively recruited 307 patients with kidney stones to complete the C-WISQOL before and after stone removal. The participants were diagnosed with UTI based on the presence of pyuria or bacteriuria with or without clinical symptoms. The psychometric properties of the C-WISQOL were statistically analyzed. Multivariate linear regression was used to predict the risk factors for impaired HRQOL in patients with stones and UTIs. The questionnaire is a reliable and robust tool for evaluating HRQOL in Chinese-speaking patients with urolithiasis. The UTI and kidney stone co-occurrence was significantly associated with female sex, diabetes mellitus, more previous stone events, higher antibiotic usage, positive stone- or UTI-related symptoms, and postoperative residual stones. The preoperative C-WISQOL scores and improvement in the HRQOL after stone removal in patients clinically diagnosed with UTI were significantly inferior to those in patients without UTI. The regression analyses showed that worse HRQOL was predicted by more previous stone events and positive stone- or UTI-related symptoms. In contrast, the presence of diabetes mellitus and postoperative residual stone fragments predicted a lower improvement in the HRQOL. These findings underscore UTI's harmful impact on perioperative HRQOL in patients with kidney stones and could help strategies benefit those patients.
In this arm, participants will attend a group meeting to practice cognitive psychotherapy once a week. They will also practice on their own \>= 4 times a week.
The test enteral nutrition formula (Inslow) and the standard balanced formula (Meibalance) were administered in a randomized crossover design to 11 healthy people, 13 IGT and 12 type-2 diabetes, judged by the postprandial state after in taking the two test meals in a random order with a washout period of one week. On the day prior to the test day, subjects were asked to stay at the same facility and to take the same supper with 450 kcal controlled, after 21:00 with only water allowed as ad libitum and not do any exercise. Each participant was taken a fasting blood sample, and then requested to consume one of is energetic test meals (200 kcal per serving) Inslow or standard balanced formula at 7:00 AM. Subsequent blood samples were collected at 30,60,90,and 120 min after meal consumption. The plasma concentrations of glucose, insulin, and free fatty acids were measured for each blood sample. Plasma glucose was measured by hexokinase method, plasma insulin by serum radioimmunoassay method and plasma free fatty acid by enzyme chemical method.Routine blood test and biochemical test were performed using the same blood sample only at fasting stage,including RBC, WBC, TP, ALP, T-Cho, etc., to confirm the status of each subject. Collected blood was applied to analyses at Shanghai Meizhong Clinical Measurement Centre. The enteral nutrition meal Inslow was designed by palatinose, dextrin and fiber as carbohydrate for 56%,23% and 15%, respectively. The standard balanced meal was included dextrin as the main carbohydrate for 85%, together with sugar and fiber.
A method of treating a patient with bioactive agents comprises providing aggregates of bioactive agents in association with liposomes, wherein the aggregates comprise liposomes having outer surfaces, and bioactive agents, wherein the bioactive agent is associated with the outer surfaces of the liposomes such that biological activity is not substantially diminished when the aggregates are administered in a pharmaceutically effective amount to a patient, and administering the aggregates to the patient. Preferred bioactive agents are TGF-β and M-CSF. A preferred method comprises aggregates of negatively-charged liposomes and TGF-β, having a net positive charge. In addition, a composition of matter comprises aggregates of TGF-β in association with liposomes. A pharmaceutical composition comprises the aggregates of TGF-β in association with liposomes in conjunction with pharmaceutically-acceptable carriers. A preferred method comprises aggregates of positively-charged liposomes and M-CSF, having a net negative charge. In addition, a composition of matter comprises aggregates of M-CSF in association with liposomes. A pharmaceutical composition comprises the aggregates of M-CSF in association with liposomes in conjunction with pharmaceutically-acceptable carriers.
The invention discloses a composition used for inhibiting tumor cell proliferation, and an application thereof. The composition is composed of quercetin and resveratrol. The molar ratio of quercetin to resveratrol is related to the ratio of 50% effective concentrations (EC50) of quercetin and resveratrol independently. The composition provided by the invention can be used for preparing any product of: (1) eukaryote tumor cell proliferation inhibitors; (2) medicines used for preventing and/or treating tumors; (3) health-care products; (4) foodstuffs; and (5) nutrient supplements. As a result of tests, a tumor cell proliferation inhibiting effect of the composition is substantially higher than that of single quercetin or single resveratrol. A combination index CI is lower than 1, such that the two components have a synergetic effect. When a same effect is reached, the dosage concentration of a single component in the composition is reduced, thus the possible potential toxicity to host normal cells is reduced.
Aim: To analyze the association of lifestyles (eating patterns, physical activity, tobacco and alcohol consumption) with the intestinal and salivate microbiota and its relationship with arterial aging and cognitive function in subjects without cardiovascular disease in Spain and Portugal. In addition, the mediating role of the intestinal microbiota in the relationship of lifestyles with arterial aging and cognitive function will be analyzed.

Design: A cross-sectional study with a case-control analysis, to analyze the association of microbiota patterns with arterial ageing. Setting: the study will develop the research network in health prevention and promotion (Rediapp) and in the Iberian network on arterial structure and the Cancer Research Center of Salamanca. Study population: 1000 subjects aged 45 to 74 years without cardiovascular disease, will be selected.

Variables: Demographic, anthropometric and habits (tobacco and alcohol). A dietary pattern through a frequency consumption questionnaire (FFQ), the software of the EVIDENT III and the Mediterranean Diet adherence questionnaire. Physical activity: International Physical Activity Questionnaire (IPAQ), Marshall Questionnaire and Accelerometer, Actigraph. Body composition (Inbody 230 impedance meter). Arterial aging: Medium intimate carotid thickness (Sonosite Micromax); Analysis (PWA) and pulse wave velocity (cf-PWV), (Sphygmocor System). Cardio Ankle Vascular Index (CAVI), ba-PWV and ankle-brachial index (Vasera VS-2000®). With Ambulatory Pulse Wave Analysis (Microsoft®), the PAIx and CAIx and the heart rate variability will be measured. The vascular damage in the retina, heart, kidney, brain and cardiovascular risk will be measured. Intestinal microbiota with the OMNIgene GUT kit (OMR -200) and analysis of the 16S rRNA microbiome profile by massive sequentiation. (Lifestyles, arterial aging, neurocognition, microbiota)
PROBLEM TO BE SOLVED: To obtain the subject base having a network frame structure including beeswax including a hydrophobic solvent, promoting the excretion of an exudate from a trauma and that of a metabolic product, supporting cutaneous respiration, increasing stability of a medicine and protecting it from contamination. SOLUTION: This base contains (A) 5-25wt.% of beeswax and (B) 95-75wt.% of a hydrophobic solvent (preferably a plant oil or an animal oil) and comprises a network frame structure including a component B in a component A. In order to obtain the objective base, the component B is first stirred on heating and making the component A liquid by heating preferably at 60-70 deg.C which is just above its melting point. The liquidized components A is then added to the component B heated to the temperature of 60-180 deg.C, thoroughly stirred and finally cooled. As an active medicines blending to the objective base, the compound such as antibiotics, β-sitosterol, etc., soluble in the component B are preferable. In order to blend an active medicine with the objective base, it is better to add the active medicine to the component B in a step of stirring the component B on heating.
The role of the oral microbiota in the overall health and in systemic diseases has gained more importance in the recent years, mainly due to the systemic effects that are mediated by the chronic inflammation caused by oral diseases, such as periodontitis, through the microbial communities of the mouth. The chronic infection by the human immunodeficiency virus (HIV) interacts at the tissue level (e.g. gut, genital tract, brain) to create reservoirs; the modulation of the gut microbiota by HIV infection is a good example of these interactions. The purpose of the present review is to assess the state of knowledge on the oral microbiota (microbiome, mycobiome and virome) of HIV-infected patients in comparison to that of HIV-negative individuals and to discuss the reciprocal influence of HIV infection and oral microbiota in patients with periodontitis on the potential establishment of a viral gingival reservoir. The influence of different clinical and biological parameters are reviewed including age, immune and viral status, potent antiretroviral therapies, smoking, infection of the airway and viral coinfections, all factors that can modulate the oral microbiota during HIV infection. The analysis of the literature proposed in this review indicates that the comparisons of the available studies are difficult due to their great heterogeneity. However, some important findings emerge: (i) the oral microbiota is less influenced than that of the gut during HIV infection, although some recurrent changes in the microbiome are identified in many studies; (ii) severe immunosuppression is correlated with altered microbiota and potent antiretroviral therapies correct partially these modifications; (iii) periodontitis constitutes a major factor of dysbiosis, which is exacerbated in HIV-infected patients; its pathogenesis can be described as a reciprocal reinforcement of the two conditions, where the local dysbiosis present in the periodontal pocket leads to inflammation, bacterial translocation and destruction of the supporting tissues, which in turn enhances an inflammatory environment that perpetuates the periodontitis cycle. With the objective of curing viral reservoirs of HIV-infected patients in the future years, it appears important to develop further researches aimed at defining whether the inflamed gingiva can serve of viral reservoir in HIV-infected patients with periodontitis.
Standard acupuncture care will be provided to persons (n=50) with chronic pain. Standard care is defined as the care a participant was already receiving and that care will not be interrupted in any way for any study participant.
PURPOSE: To obtain a 5α-reductase inhibitor which contains, as an active ingredient, a solvent extract from a specific plant which has been taken by human for a long period of time and confirmed to be safe to human body, and shows marked hair-growing effect. CONSTITUTION: Bark of Cassia auriculata, fruit of Quercus pedunculata and leaf of Rumex cyprius are extracted with water or a hydrophilic organic solvent such as ethanol to give an extract of 5α-reductase inhibitor. In the extraction, a polyhydric alcohol such as glycerol or 1,3-butylene glycol or an aqueous solution thereof also may be employed. This substance is added to other cosmetic materials to give a variety of anti-α-reductase preparation forms and can be utilized in the form of lotion, emulsion, pack or the like. Since the 5α-reductase inhibitor inhibits the activity of reductases which inhibit hair from growing, it may be formulated to a hair tonic agent to increase the hair-growing effect. The plants have been used as herbs for many years and so can be applied to skin safely.
The eligible patients are assigned to the experimental group (microtransplantation group, MST group) or the control group (CT) according to the availability of suitable donors. In MST group, peripheral blood hematopoietic stem cells from HLA mismatched donors mobilized with granulocyte colony stimulating factor are infused after conventional chemotherapy and/or radiotherapy ; The CT group only received conventional chemotherapy and/or radiotherapy. According to the patient's past medical history, current tumor assessment results, and the latest cancer treatment guidelines, the individualized chemotherapy and / or radiotherapy plan for the patient is formulated after discussion by more than 3 oncologists. After each course of treatment, the efficacy and safety are evaluated. For the patients who are evaluated to be effective or stable (SD) after the first treatment, the second treatment of the same scheme will be given. Those who reach the disease control level will continue to be treated for 4 courses, with an interval of 28 days. The patients who failed to achieve the improvement of SD after two cycles of chemotherapy will be withdrawn from the study. Patients are allowed to receive any treatment, including symptomatic support treatment, after the end of treatment or withdrawal from the study.
Patients receive treatment as in Arm C. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
According to study records, IL-2 has not been tested in HIV-infected children. Experience with IL-2 in pediatric populations is extremely limited. Pahwa et al. gave 30,000 units/kg daily IV to a child with severe combined immunodeficiency. This dose was well tolerated and the patient improved clinically as well as immunologically. Part A is necessary to determine the maximum tolerated dose of IL-2 in infected children. Part B will determine the efficacy of the maximum tolerated dose in infected children.

Part A: Children will receive rIL-2 intravenously for 5 days every 8 weeks for 3 cycles. The study will enroll 4 patients in each of 3 dose levels. Dose escalation may occur if all 4 patients in a dose level tolerate therapy without evidence of Grade 3 (or higher) toxicity. If 1 of 4 subjects in any dose level experiences at least Grade 3 toxicity, 2 additional patients will be enrolled in that dose level. If 1 of these 2 additional patients experiences at least Grade 3 toxicity, dose escalation will not proceed. NOTE: Once Part A is completed and the maximum tolerated dose is established, children who participated in Part A and received less than the maximum tolerated dose will be offered additional therapy consisting of 3 cycles of rIL-2 at the maximum tolerated dose.

Part B: Children will receive rIL-2 intravenously at the maximum tolerated dose established in part A. Treatment will be given for 5 days every 8 weeks for 3 cycles. \[AS PER AMENDMENT 6/4/98: Children will receive rIL-2 intravenously at the lowest dose for 5 days every 8 weeks for 6 cycles. Patients who received this dose in part A will also be offered this regimen.\]
PROBLEM TO BE SOLVED: To obtain a cosmetic improved in feeling in use, excellent in dispersibility of powder and durability of makeup such as water resistance/sweat resistance, oil resistance/sebum resistance, by using a lower alcohol, hydrophobilyzation treated powder and a specific hydrophilic silicone. SOLUTION: This cosmetic is obtained by combining (A) a copolymer which contains a hydrophilic segment and an organopolysiloxane segment and is soluble or dispersible in water or a lower alcohol with (B) a lower alcohol and (C hydrophobilization treated powder. A segment which is bonded through a hetero atom-containing alkylene group to at least one silicon atom at the end or a side chain of the organopolysiloxane segment and contains a repeating unit of formula I (R<1> is H, an alkyl, etc.; (n) is 2 or 3) or formula II (R<2> is H, an alkyl, etc.; (r) is 1-5) is preferable as the hydrophilic segment of the component A. The system may be further mixed with an oil component such as a silicone oil, water, an inorganic salt or an organic acid salt.
FIELD: medicine; surgery. SUBSTANCE: method involves splenectomy, formation of fragments and their heterotopic implantation, and intraoperational anti-ischemic protection of the spleen before ablation. Antioxidants are administered intravenously. After splenectomy, the spleen is perfused with hyperosmolar solution with addition of the highest single dose of antioxidants and calcium-antagonistic agents. The fragments are formed as anatomic subsegments of the organ to be implanted on the cross fascia in the projection of the lower third of the transverse abdominal muscle. For this purpose, an additional transrectal cut is done. The post-surgery treatment involves therapy with antibacterial drugs and antioxidants. EFFECT: more reliable prevention of intra-abdominal complications.
The study will assess the impact of Life Skill Building (LSB) to Benazir Income support Program (BISP) Cash Transfer (CT) beneficiaries and their husbands in improving maternal mental and child health and its combined effect in empowering women and couples. The Formative phase of the project was dedicated for the development and modification of National level LSB curriculum for men and women. The formative phase was carried out in Thatta (Sindh), Rahimyar Khan (Punjab), Lasbela (Baluchistan) and Peshawar (KPK).

The intervention phase will be conducted in district Thatta, where BISP beneficiaries along with their spouses will be offered a LSB training. This intervention will be offered by community teachers to ensure sustainability and community trust. The participants will be recruited for baseline assessment followed by a comprehensive LSB intervention.The end-line follow up assessments (five months of intervention) will be done after the deliver of intervention. A qualitative summative inquiry will be done at the completion of the project to explore the overall impact of the LSB intervention. Since the project is being implemented with the BISP, the cost of intervention can be estimated for the scalability and sustainability.
Our group recently completed a randomized controlled trial evaluating the efficacy of providing 5 weeks of free NRT (in the form of the nicotine patch) by expedited postal mail without behavioural assistance to regular adult smokers recruited across Canada interested in receiving it (clinicaltrials.gov Identifier: NCT01429129). The findings revealed that the provision of free nicotine patches via mail resulted in more than a doubling of 30-day abstinence quit rates at a six-month follow-up compared to the no intervention control group (7.6% versus 3.0%; odds ratio of 2.65). While this trial provided evidence for the effectiveness of nicotine patches as a tobacco cessation aid in real world settings, the findings speak only to the short-term effectiveness of NRT. As evidence for NRT effectiveness has been largely restricted to a final follow-up of 6-12 months after the start of treatment, and relapse to smoking is known to occur beyond this period, it is important to evaluate whether the net benefit of NRT in naturalistic settings can be maintained long-term.

Employing a survey research call centre, trained interviewers will contact participants in the original randomized controlled trial, 5 years post-enrollment. A total of 924 subjects will be eligible to be contacted, however intent-to-treat analyses will evaluate outcomes based on all 1000 participants randomized to condition in the original trial. In this 5-year follow-up survey, interviewers will first assess participants' smoking status, the number of cigarettes smoked per day and their level of nicotine dependence. Participants reporting not currently smoking will be asked whether they have smoked tobacco, even a puff, in the last 30 days (primary outcome measure: abstinence using 30 day point prevalence), past 6 months (secondary outcome measure: prolonged 6-month abstinence), and since the last follow-up survey (secondary outcome measure: \> 4 year continuous abstinence). Interviewers will be blind to experimental condition at the time the primary outcome measure will be assessed. The survey component of the proposed study will be conducted over a 2 year period to coincide with the duration of subject recruitment in the original trial. The primary hypothesis is that subjects who received nicotine patches at baseline will display significantly higher quit rates at the 5-year follow-up as compared to subjects who did not receive nicotine patches at baseline.
<P>PROBLEM TO BE SOLVED: To impart excellent damage repairing effects on hair, receiving chemical damage with a hair dye or perming, etc., to a hair cosmetic by repairing from the outside.  <P>SOLUTION: A treatment frequently using a protein hydrolyzate such as supplementation of the protein hydrolyzate having high hair repairing effects or formation of a film from a product prepared by silylating the protein hydrolyzate on the surface of hair to improve the texture of the hair is conventionally a well-known fact. It is however hard to say that the treatment is satisfactory in the repairing effects on defective settlement resulting from hair damage. As a result of various studies made on quaternized polymers, good effects imparting excellent conditioning effects such as impartment of good retention to the hair, a reduction in chemical damage with the hair dye or perming, etc., a reduction in floating with static electricity or a reduction in frizz are found out by formulating a quaternized corn starch. Thereby, development is made.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The present invention relates to a pharmaceutical composition and health-aid food comprising an extract of Salicornia spp. as an active ingredient for preventing or treating thrombosis. More particularly, the present invention relates to a pharmaceutical composition and health-aid food comprising extract of Salicornia spp. as an active ingredient for preventing or treating/overcoming thrombosis by inhibiting blood coagulation and platelet aggregation. The extract of Salicornia spp. as an active ingredient of a pharmaceutical composition and health-aid food for preventing or treating thrombosis according to the present invention inhibits thrombosis-related enzymes and blood coagulation factors and suppresses aggregation of platelets functioning as initiators of thrombosis, thereby providing strong anti-thrombotic activity. In addition, the extract shows no hemolytic activity to human red blood cells, has excellent thermal stability and causes no loss of an effect of inhibiting blood coagulation factors and thrombosis-related enzymes. Thus, it is expected that the extract can be used for preventing and treating thrombosis, such as ischemic stroke and hemorrhagic stroke, through the improvement of blood circulation. The active ingredient is processed into various forms, such as extract, powder, pills and tablets, so that it may be administered any time. Thus, the present invention is useful for pharmaceutical industry and food industry.